Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 62013TN0134

Case T-134/13: Action brought on 28 February 2013 — Polynt and Sitre v ECHA

OJ C 129, 4.5.2013, p. 26–26 (BG, ES, CS, DA, DE, ET, EL, EN, FR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

4.5.2013   

EN

Official Journal of the European Union

C 129/26


Action brought on 28 February 2013 — Polynt and Sitre v ECHA

(Case T-134/13)

2013/C 129/50

Language of the case: English

Parties

Applicants: Polynt SpA (Scanzorosciate, Italy); and Sitre Srl (Milan, Italy) (represented by: C. Mereu and K. Van Maldegem, lawyers)

Defendant: European Chemicals Agency (ECHA)

Form of order sought

The applicants claim that the Court should:

Declare the application admissible and well-founded;

Partially annul Decision ED/169/2012 of the ECHA concerning the inclusion of cyclohexane-1,2-dicarboxylic anhydride, cis-cyclohexane-1,2-dicarboxylic anhydride and trans-cyclohexane-1,2-dicarboxylic anhydride (collectively referred to as ‘HHPA’) as Substances meeting the criteria set out in Article 57(f) of Regulation (EC) No 1907/2006 (1) (‘REACH’), in accordance with Article 59 of REACH, as it relates to HHPA and its monomers; and

Order the defendant to pay the costs of these proceedings.

Pleas in law and main arguments

In support of the action, the applicants rely on three pleas in law.

1.

First plea in law, alleging manifest error of assessment/law: (i) respiratory sensitisers are not covered by Article 57(f) of REACH and (ii) the ECHA did not provide sufficient justification and evidence in order to demonstrate that HHPA was of ‘equivalent concern’ to a carcinogen, mutagen or toxicant for reproduction (‘CMR’), category 1, since:

CMR substances trigger irreversible effects whereas, in the case of HHPA, the effects of respiratory sensitisation are not irreversible;

there is no consumer or worker exposure to HHPA;

the assessment of HHPA is based on data which is old and outdated; and

the assessment did not take into account all relevant data.

2.

Second plea in law, alleging breach of the rights of defence, as the applicants did not have the opportunity to fully defend their case because of the lack of objective criteria for considering whether a substance is of equivalent concern according to Article 57(f) REACH, especially in the case of a respiratory sensitiser such as HHPA, and because ECHA did not take into account all information available or provided by the industry during the commenting period.

3.

Third plea in law, alleging infringement of the principle of proportionality, as the ECHA had a choice of measures with respect to HHPA and by identifying HPPA as Substance of Very High Concern (‘SVHC’) caused the applicants disadvantages which are disproportionate in relation to the aims pursued.


(1)  Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC (OJ 2006 L 396, p. 1)


Top